EUVIMEDEUVIMED entdecken
Kontrollierte klinische StudieOpen Access · CC BY 4.0

The significance of upfront autologous stem cell transplantation for high‐intermediate/high‐risk stage IV diffuse large B‐cell lymphoma

Aleksei K Koviazin iD, Larisa V Filatova iD, Ilia S Zyuzgin, Anna S Artemyeva, Ilia L Poliatskin, Darya S Burda, Stanislav A Volchenkov iD, Svetlana S Elkhova iD, Tatiana Yu Semiglazova iD

Cancer Reports · 2023

DOI: 10.1002/cnr2.1786 ↗

Kurz gefasst

Kontrollierte klinische Studie in der Zeitschrift Cancer Reports, 2023. Verfasst von Aleksei K Koviazin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Chemotherapy with Intensive Care Unit, NMRC of Oncology n.a. N.N.Petrov of MoH of Russia, Federal State Budgetary Instit…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diffuse large B‐cell lymphoma (DLBCL) is the most common (30%–35%) type of B‐cell lymphoma. Only about 60% of all newly diagnosed advanced‐stage DLBCL can be completely treated with x6 R‐CHOP. High‐dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation in the first remission (upfront auto‐HSCT) can serve as an option to improve a prognosis in these patients.

Aims

This trial aimed to improve prognosis in DLBCL by upfront auto‐HSCT. Methods and Results A group of 105 patients: DLBCL NOS, age 18–65, stage IV, IPI ≥2, CR/PR after x6 R‐CHOP/DA‐EPOCH‐R from 2010 to 2019 at NMRC of Oncology named after N.N.Petrov of MoH of Russia was retrospectively analyzed. The HSCT group included patients with upfront HDCT followed by auto‐HSCT ( n = 35). The control group included patients with non‐invasive follow‐up after induction ( n = 70). Primary endpoint was progression‐free survival (PFS). Secondary endpoints were overall survival (OS), response rate and relapse rate. The 3‐year OS ( p = .013) and 3‐year PFS ( p = .033) were significantly higher in the HSCT group. The 3‐year OS was decreased by the occurrence of relapse ( p ≤ .001) and weight loss (B‐symptom) ( p = .04). DEL was the negative prognostic factor for 3‐year PFS in all patients ( p = .001) and control group ( p = .001). DA‐EPOCH‐R significantly increased the 3‐year PFS ( p = .041).

Conclusion

Upfront HDCT followed by auto‐HSCT can increase 3‐year OS and PFS and improve prognosis in DLBCL NOS, age 18–65, stage IV, IPI ≥2 patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationLymphoma, Large B-Cell, DiffuseAdolescentAdultAgedHumansMiddle AgedYoung AdultNeoplasm Recurrence, LocalRetrospective StudiesTransplantation, Autologous

Stichwörter der Autor:innen

autologous hematopoietic stem cell transplantationdiffuse large B-cell lymphomahigh-riskstage IV

Autor:innen und Institutionen

  • Department of Hematology and Chemotherapy with Intensive Care Unit, NMRC of Oncology n.a. N.N.Petrov of MoH of Russia, Federal State Budgetary Institution "Petrov National Medical Cancer Research Centre" of the Ministry…
  • Department of Innovative Methods in Therapeutic Oncology and Rehabilitation, NMRC of Oncology n.a. N.N.Petrov of MoH of Russia, Federal State Budgetary Institution "Petrov National Medical Cancer Research Centre" of the…
  • Department of Oncology, Federal State Budgetary Educational Institution of Higher Education "North-Western State Medical University named after I.I. Mechnikov" of the Ministry of Health of the Russian Federation, Saint-…
  • Laboratory of Tumor Morphology, Federal State Budgetary Institution "Petrov National Medical Cancer Research Centre" of the Ministry of Health of the Russian Federation, Saint-Petersburg, Russian Federation.

ORCID-Profile: Aleksei K Koviazin, Larisa V Filatova, Stanislav A Volchenkov, Svetlana S Elkhova, Tatiana Yu Semiglazova

Zitieren

APA

Koviazin, A. K., Filatova, L. V., Zyuzgin, I. S., Artemyeva, A. S., Poliatskin, I. L., Burda, D. S., Volchenkov, S. A., Elkhova, S. S., & Semiglazova, T. Y. (2023). The significance of upfront autologous stem cell transplantation for high‐intermediate/high‐risk stage IV diffuse large B‐cell lymphoma. Cancer Reports. https://doi.org/10.1002/cnr2.1786

Vancouver

Koviazin AK, Filatova LV, Zyuzgin IS, Artemyeva AS, Poliatskin IL, Burda DS, et al. The significance of upfront autologous stem cell transplantation for high‐intermediate/high‐risk stage IV diffuse large B‐cell lymphoma. Cancer Reports. 2023. doi:10.1002/cnr2.1786

BibTeX
@article{Koviazin2023,
  author = {Koviazin, Aleksei K and Filatova, Larisa V and Zyuzgin, Ilia S and Artemyeva, Anna S and Poliatskin, Ilia L and Burda, Darya S and Volchenkov, Stanislav A and Elkhova, Svetlana S and Semiglazova, Tatiana Yu},
  title = {The significance of upfront autologous stem cell transplantation for high‐intermediate/high‐risk stage IV diffuse large B‐cell lymphoma},
  journal = {Cancer Reports},
  year = {2023},
  doi = {10.1002/cnr2.1786}
}
Kostenlos starten →